FDA Rejects 2 Gilead Sciences HIV Drugs

Gilead Sciences (NASDAQ: GILD  ) has received notice from the Food and Drug Administration that it is withholding approval of two drugs meant to be used as part of an HIV treatment regimen, the company announced today.

The FDA wrote Gilead that the reasons for not approving the new drug applications for elvitegravir and cobicistat were observed deficiencies in documentation and the validation of some quality testing procedures and methods.

Gilead Sciences said that though elvitegravir and cobicistat are components of its HIV drug Stribild, the FDA action does not affect the marketing of or continued use of Stribild.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2395194, ~/Articles/ArticleHandler.aspx, 4/17/2014 7:05:28 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASD 4,086.23 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/16/2014 4:00 PM
GILD $69.28 Up +1.11 +1.63%
Gilead Sciences CAPS Rating: ****

Advertisement